Medtronic sees RESOLUTE trial data promise for next-generation drug-eluting stent
This article was originally published in Clinica
Medtronic has released positive nine-month results from a clinical trial of its next-generation drug-eluting stent (DES), Endeavor Resolute.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.